Difference between revisions of "Example orders for adjuvant Interferon alfa-2b (Intron-A) in melanoma"
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.'''" to "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''") |
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth") |
||
Line 1: | Line 1: | ||
− | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' | + | {|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" |
+ | | | ||
+ | <span style="font-family:Arial; font-size:200%"> Hello!<br> | ||
+ | We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> | ||
+ | Please help us by filling it out!<br> | ||
+ | '''Link:''' http://j.mp/2BlBaoQ | ||
+ | </span> | ||
+ | |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' | ||
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. |
Revision as of 21:07, 30 December 2017
Hello! |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
Interferon alfa-2b (Intron-A)
Published regimens and references can be found on the melanoma page.
Example order set #1 (5 days per week)
Induction phase
- Interferon alfa-2b (Intron-A) 20,000,000 units/m2 IV once per day on days 1, 2, 3, 6, 7
7-day cycles x 4 cycles, then proceed to maintenance phase
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO once 30 minutes prior to interferon
- Naproxen (Naprosyn) 375 mg PO Q12H prn fevers, chills, myalgias, headache if acetaminophen not effective
- Lorazepam (Ativan) 0.5 to 1 mg PO once prn nausea/anxiety 30 minutes prior to chemotherapy
Hydration:
- Normal saline 500 mL IV bolus over 20 minutes prior to interferon
- Normal saline IV continuous infusion at 5 mL/H during administration of interferon
- Normal saline 25 to 50 mL IV prn flush before and after chemotherapy
Nursing:
- Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
- Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.
Maintenance phase
Frequency and dose may need to be adjusted based on patient's tolerance of induction phase.
- Interferon alfa-2b (Intron-A) 10,000,000 units/m2 SC three times per week
48-week course
Example order set #2 (3 days per week)
Induction phase
- Interferon alfa-2b (Intron-A) 20,000,000 units/m2 IV once per day on days 3, 6, 7
7-day cycles x 4 cycles, then proceed to maintenance phase
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO once 30 minutes prior to interferon
- Naproxen (Naprosyn) 375 mg PO Q12H prn fevers, chills, myalgias, headache if acetaminophen not effective
- Lorazepam (Ativan) 0.5 to 1 mg PO once prn nausea/anxiety 30 minutes prior to chemotherapy
Hydration:
- Normal saline 500 mL IV bolus over 20 minutes prior to interferon
- Normal saline IV continuous infusion at 5 mL/H during administration of interferon
- Normal saline 25 to 50 mL IV prn flush before and after chemotherapy
Nursing:
- Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
- Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.
Maintenance phase
Frequency and dose may need to be adjusted based on patient's tolerance of induction phase.
- Interferon alfa-2b (Intron-A) 10,000,000 units/m2 SC three times per week
48-week course
Example order set #3 (2 days per week)
Induction phase
- Interferon alfa-2b (Intron-A) 20,000,000 units/m2 IV once per day on days 6 & 7
7-day cycles x 4 cycles, then proceed to maintenance phase
Supportive medications
- Acetaminophen (Tylenol) 1000 mg PO once 30 minutes prior to interferon
- Naproxen (Naprosyn) 375 mg PO Q12H prn fevers, chills, myalgias, headache if acetaminophen not effective
- Lorazepam (Ativan) 0.5 to 1 mg PO once prn nausea/anxiety 30 minutes prior to chemotherapy
Hydration:
- Normal saline 500 mL IV bolus over 20 minutes prior to interferon
- Normal saline IV continuous infusion at 5 mL/H during administration of interferon
- Normal saline 25 to 50 mL IV prn flush before and after chemotherapy
Nursing:
- Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
- Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.
Maintenance phase
Frequency and dose may need to be adjusted based on patient's tolerance of induction phase.
- Interferon alfa-2b (Intron-A) 10,000,000 units/m2 SC three times per week
48-week course